Abstract
Objective
To examine the association of a healthy sleep pattern, characterized by sleep of 7
to 8 h/d, morning person, no insomnia, no frequent snoring, and no daytime sleepiness,
with the risk of chronic kidney disease (CKD).
Methods
We included 392,218 European adults, aged 38 to 73 years, who were free of CKD at
recruitment between March 13, 2006, and October 1, 2010, from the UK Biobank study.
Data on sleep behaviors were collected through questionnaires at recruitment. Cox
proportional hazards regression models were used to assess the relations between the
healthy sleep score and risk of CKD.
Results
We identified 18,842 incident CKD cases after a mean follow-up of 11.1 (SD 2.2) years.
The healthy sleep score was inversely associated with the risk of CKD in a dose-dependent
manner (P for trend, <.001). Compared with the participants with a poor sleep pattern (score
of 0-1), the multivariate adjusted hazard ratio of CKD was 0.77 (95% CI, 0.71 to 0.84)
for those with the healthiest sleep pattern (score of 5). In addition, we found that
the inverse association was stronger in individuals without history of hypertension
compared with individuals with hypertension at baseline (P for interaction, .003) and in those 60 years of age or younger compared with their
older counterparts (P for interaction, <.001).
Conclusion
Our data suggest that adherence to an overall healthy sleep pattern is associated
with a lower risk of CKD, especially for individuals without history of hypertension
and those who are younger.
Abbreviations and Acronyms:
BMI (body mass index), CKD (chronic kidney disease), CVD (cardiovascular disease), eGFR (estimated glomerular filtration rate), GCSE (General Certificate of Secondary Education), HR (hazard ratio), MET (metabolic equivalent), PSQI (Pittsburgh Sleep Quality Index)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Evolving importance of kidney disease: from subspecialty to global health burden.Lancet. 2013; 382: 158-169
- Chronic kidney disease.Lancet. 2017; 389: 1238-1252
- Challenges of conducting a trial of uric-acid-lowering therapy in CKD.Nat Rev Nephrol. 2011; 7: 295-300
- Risk factors for prognosis in patients with severely decreased GFR [erratum appears in Kidney Int Rep. 2018;3(6):1506].Kidney Int Rep. 2018; 3: 625-637
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.Lancet. 2013; 382: 339-352
- Association of short sleep duration and rapid decline in renal function.Kidney Int. 2016; 89: 1324-1330
- Self-reported sleep duration and prediction of proteinuria: a retrospective cohort study.Am J Kidney Dis. 2012; 59: 343-355
- Short or long sleep duration and CKD: a mendelian randomization study.J Am Soc Nephrol. 2020; 31: 2937-2947
- A prospective cohort study of insomnia and chronic kidney disease in Japanese workers.Sleep Breath. 2018; 22: 257-265
- Snoring and incident chronic kidney disease: a community-based prospective cohort study.BMJ Open. 2019; 9: e030671
- Self-reported snoring is associated with chronic kidney disease independent of metabolic syndrome in middle-aged and elderly Chinese.J Diabetes Investig. 2019; 10: 124-130
- Sleep quality and sleep duration with CKD are associated with progression to ESKD.Clin J Am Soc Nephrol. 2018; 13: 1825-1832
- Sleep homeostasis, habits and habituation.Curr Opin Neurobiol. 2017; 44: 202-211
- Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants.Eur Heart J. 2020; 41: 1182-1189
- Adherence to a healthy sleep pattern and incident heart failure: a prospective study of 408 802 UK Biobank participants.Circulation. 2021; 143: 97-99
- Baseline vitamin D status, sleep patterns, and the risk of incident type 2 diabetes in data from the UK Biobank study.Diabetes Care. 2020; 43: 2776-2784
- UK Biobank: bank on it.Lancet. 2007; 369: 1980-1982
- UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.PLoS Med. 2015; 12: e1001779
- A new equation to estimate glomerular filtration rate [erratum appears in Ann Intern Med. 2011;155(6):408].Ann Intern Med. 2009; 150: 604-612
- Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease [erratum appears in Nat Med. 2020;26(8):1308].Nat Med. 2019; 25: 1753-1760
- Objective sleep, a novel risk factor for alterations in kidney function: the CARDIA study.Sleep Med. 2014; 15: 1140-1146
- Sleep duration and risk of end-stage renal disease: the Singapore Chinese Health Study.Sleep Med. 2019; 54: 22-27
- Association of chronic insomnia with mortality and adverse renal outcomes.Mayo Clin Proc. 2018; 93: 1563-1570
- The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.Psychiatry Res. 1989; 28: 193-213
- Circadian rhythms and the kidney.Nat Rev Nephrol. 2018; 14: 626-635
- Associations of chronotype and sleep with cardiovascular diseases and type 2 diabetes.Chronobiol Int. 2013; 30: 470-477
- United States Renal Data System 2018 annual data report: epidemiology of kidney disease in the United States.Am J Kidney Dis. 2019; 73 (S1-S772): A7-A8
- Sleep duration and biomarkers of inflammation.Sleep. 2009; 32: 200-204
- Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk.J Am Col. Cardiol. 2004; 43: 678-683
- Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers.Sleep. 2007; 30: 1145-1152
- Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis.Diabetes Care. 2010; 33: 414-420
- Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies.Diabetes Care. 2015; 38: 529-537
- Apneic sleep, insufficient sleep, and hypertension.Hypertension. 2019; 73: 744-756
- Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a Scientific Statement from the American Heart Association.Circulation. 2016; 134: e367-e386
- Chronic kidney disease.Nat Rev Dis Primers. 2017; 3: 17088
- The renal consequences of arterial hypertension.Kidney Int. 1997; 51: 1639-1653
- Multiple, objectively measured sleep dimensions including hypoxic burden and chronic kidney disease: findings from the Multi-Ethnic Study of Atherosclerosis.Thorax. 2021; 76: 704-713
- Obstructive sleep apnea and kidney disease: is there any direct link?.Sleep Breath. 2012; 16: 1009-1016
- Sleep characteristics across the lifespan in 1.1 million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis.Nat Hum Behav. 2021; 5: 113-122
- Chronic kidney disease and coronary artery disease: JACC state-of-the-art review.J Am Coll Cardiol. 2019; 74: 1823-1838
Article Info
Footnotes
Grant Support: The study was supported by grants from the National Heart, Lung, and Blood Institute ( HL071981 , HL034594 , HL126024 ) and the National Institute of Diabetes and Digestive and Kidney Diseases ( DK115679 , DK091718 , DK100383 , DK078616 ).
Potential Competing Interests: The authors report no competing interests.
Data Sharing: The UK Biobank data are available on application to the UK Biobank (www.ukbiobank.ac.uk/).
Identification
Copyright
© 2021 Mayo Foundation for Medical Education and Research
ScienceDirect
Access this article on ScienceDirectLinked Article
- Healthy Sleep for Healthy Kidneys—It Takes a VillageMayo Clinic ProceedingsVol. 97Issue 1
- PreviewAffecting nearly 700 million people globally, chronic kidney disease (CKD) contributes substantially to disability and reduced survival, with more than 1.2 million directly attributable deaths worldwide in 2017.1 With cardiovascular disease being a major and often fatal complication of CKD, mortality more than doubles when cardiovascular deaths due to impaired renal function are included. Symptom burden, reduced quality of life, and increased health care expenditures add to the burden of CKD on individuals and societies.
- Full-Text
- Preview
